GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Olanzapine oral tablets (single agent)

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug2 sources available - open source summaries, references and comparisons

Zyprexa

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Olanzapine oral tablets (single agent) - selected U.S. label sections

Product / population
Selected U.S. single-agent olanzapine oral tablet label. Not LYBALVI or a long-acting injectable.
Renal measure
Qualitative degree of renal impairment in PK section

Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.

Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.

Renal and dialysis comments

Renal dysfunction alone does not require olanzapine dose adjustment. Pharmacokinetics were similar in severe impairment and normal renal function. Olanzapine is not removed by dialysis; renal effects on metabolite elimination have not been studied.

Combination-product distinction

Do not apply this single-agent statement to olanzapine/samidorphan; that combination has a separate ESRD restriction.

Source revision: Revision not captured; retrieval date is not the revision date. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8626e68-088d-47ff-bf06-489a778815aa

Scope: Local label summary; independent clinical review pending. Not a two-source validated protocol. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Official product label

Olanzapine oral tablets (single agent) - selected U.S. label sections

Selected U.S. single-agent olanzapine oral tablet label. Not LYBALVI or a long-acting injectable.

Renal method: Qualitative degree of renal impairment in PK section
Retrieved: 2026-09-05

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - ZYPREXA

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Single-agent oral olanzapine; not a long-acting injection or combination tablet.

Renal method: Qualitative renal impairment and dialysis; metabolite evidence limited.
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.
Official source

Olanzapine oral tablets (single agent) - selected U.S. label sections

Selected U.S. single-agent olanzapine oral tablet label. Not LYBALVI or a long-acting injectable.

Method: Qualitative degree of renal impairment in PK section

Renal and dialysis commentsRead this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeOlanzapine oral tablets (single agent) - selected U.S. label sectionsGlobalRPh RX List - ZYPREXA
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8626e68-088d-47ff-bf06-489a778815aa

Product and population scope

Selected U.S. single-agent olanzapine oral tablet label. Not LYBALVI or a long-acting injectable.

RDM32-olanzapine-oral-tablets-scope · Source section: Editorial scope for the selected U.S. labelRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Olanzapine oral tablets (single agent) - selected U.S. label sections

Open original reference

Open / share this exact local source

U.S. product labeling / DailyMed · Selected U.S. single-agent olanzapine oral tablet label. Not LYBALVI or a long-acting injectable.

Renal method: Qualitative degree of renal impairment in PK section
Source date: Revision not captured; retrieval date is not the revision date.
Retrieved: 2026-09-05

Local label summary; independent clinical review pending. Not a two-source validated protocol.

Renal and dialysis comments

Renal dysfunction alone does not require olanzapine dose adjustment. Pharmacokinetics were similar in severe impairment and normal renal function. Olanzapine is not removed by dialysis; renal effects on metabolite elimination have not been studied.

RDM32-olanzapine-oral-tablets-1 · Source locator: 12.3, Renal Impairment

Combination-product distinction

Do not apply this single-agent statement to olanzapine/samidorphan; that combination has a separate ESRD restriction.

RDM32-olanzapine-oral-tablets-2 · Source locator: Editorial formulation boundary; see separate LYBALVI source entry

Source-specific limits

Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.

Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8626e68-088d-47ff-bf06-489a778815aa
Retrieved
2026-09-05
DailyMed Set ID
e8626e68-088d-47ff-bf06-489a778815aa
Renal-function method
Qualitative degree of renal impairment in PK section
Source date/version
Revision not captured; retrieval date is not the revision date.
Hash meaning
SHA-256 identifies this local summary, not original SPL XML or a label PDF.
Local summary SHA-256
e0c90195cff8fb921cb585d73fc06f755fb4f0658d5c1ecd051d74fc623e4944
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - ZYPREXA

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Single-agent oral olanzapine; not a long-acting injection or combination tablet.

Renal method: Qualitative renal impairment and dialysis; metabolite evidence limited.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Renal dysfunction alone does not require a dose adjustment in the selected source. Olanzapine is not removed by dialysis; renal effects on metabolite elimination have not been studied. Keep those limitations separate from the parent-drug dosing statement. This does not authorize extrapolation to a depot or an olanzapine combination product.

RDM37-rxlist-olanzapine-oral-tablets-b4fa37e76e-C1 · Source locator: Clinical Pharmacology: Renal Impairment.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/zyprexa-drug/
Retrieved
2026-09-07
Renal-function method
Qualitative renal impairment and dialysis; metabolite evidence limited.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
65b5a226b641bf25bb85f6f5463d87fab0e33fb3b4022596ab59f9396ae3a7bf

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8626e68-088d-47ff-bf06-489a778815aa
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
e274329b5d45df2a4ddb8d369d1fcb943ecc63e2075b4915efdca9dd4e22954d
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report